2.68

0.75% 0.02

Pre-market: 2.70 0.02 +0.75%

Ovid Therapeutics Inc (OVID)

Overview News Price History Option Chain Financials Discussions Forecast

Ovid Therapeutics Inc stock is traded at $2.68, with a volume of 1.83M. It is up +0.75% in the last 24 hours and up +5.10% over the past month. Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

Previous Close:

$2.66

Open:

$2.69

24h Volume:

1.83M

Relative Volume:

0.61

Market Cap:

$463.74M

Revenue:

$7.25M

Net Income/Loss:

$-17.41M

P/E Ratio:

-10.20

EPS:

-0.2627

Net Cash Flow:

$-38.33M

1W Performance:

-4.29%

1M Performance:

+5.10%

6M Performance:

+71.79%

1Y Performance:

+724.62%

1-Day Range:

$2.58

$2.77

1-Week Range:

$2.58

$2.97

52-Week Range:

$0.2701

$3.105

Ovid Therapeutics Inc Stock (OVID) Company Profile

Name

Ovid Therapeutics Inc

Sector

Healthcare (1111)

Industry

Biotechnology (620)

Phone

212-776-4381

Address

441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY

Employee

Twitter

@OvidRx

Next Earnings Date

2026-05-12

Latest SEC Filings

OVID's Discussions on Twitter

Compare OVID vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OVID Ovid Therapeutics Inc	2.68	463.74M	7.25M	-17.41M	-38.33M	-0.2627
VRTX Vertex Pharmaceuticals Inc	435.10	110.67B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	766.02	80.98B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	787.95	49.00B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.79	41.87B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	299.81	33.28B	5.36B	287.73M	924.18M	2.5229

Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-11-25	Initiated	Roth Capital	Buy
Nov-17-25	Initiated	Leerink Partners	Outperform
Oct-09-25	Initiated	Oppenheimer	Outperform
Aug-08-25	Resumed	B. Riley Securities	Buy
Jun-18-24	Downgrade	Oppenheimer	Outperform → Perform
Apr-30-24	Initiated	B. Riley Securities	Buy
Apr-29-24	Initiated	H.C. Wainwright	Buy
Apr-05-24	Initiated	Wedbush	Outperform
Dec-21-23	Initiated	BTIG Research	Buy
Oct-13-23	Initiated	Oppenheimer	Outperform
Apr-20-21	Downgrade	Cantor Fitzgerald	Buy → Neutral
Mar-03-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Dec-02-20	Downgrade	Citigroup	Buy → Neutral
Dec-02-20	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-04-19	Initiated	RBC Capital Mkts	Outperform
Apr-20-18	Initiated	Ladenburg Thalmann	Buy

View All

Ovid Therapeutics Inc Stock (OVID) Latest News

Apr 23, 2026

OVID Ovid Therapeutics Inc. far exceeds Q4 2025 EPS expectations, shares rise nearly four percent.Profit Guidance - Cổng thông tin điện tử Tỉnh Sơn La

Apr 23, 2026

Apr 22, 2026

OVID (Ovid Therapeutics) delivers blowout Q4 2025 results, but stock dips slightly amid mild investor profit taking.Deceleration Risk - Xã Thanh Hà

Apr 22, 2026

Apr 21, 2026

29.86M-share resale registration by Ovid Therapeutics (NASDAQ: OVID) - Stock Titan

Apr 21, 2026

Apr 20, 2026

H.C. Wainwright reiterates Ovid Therapeutics stock rating at buy By Investing.com - Investing.com India

Apr 20, 2026

Ovid Therapeutics receives $53.9 million from warrant exercises By Investing.com - Investing.com India

Apr 20, 2026

Ovid Therapeutics Boosts Capital Through Warrant Exercises - TipRanks

Apr 20, 2026

Ovid Therapeutics receives $53.9 million from warrant exercises - Investing.com

Apr 20, 2026

Ovid Therapeutics sees $53.9M gross proceeds as Series A warrants mostly exercised - TradingView

Apr 20, 2026

Warrant exercises bring Ovid Therapeutics (NASDAQ: OVID) $53.9M cash - Stock Titan

Apr 20, 2026

H.C. Wainwright reiterates Ovid Therapeutics stock rating at buy - Investing.com

Apr 20, 2026

Apr 18, 2026

William Blair Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Announces Target Price $5.24 - 富途牛牛

Apr 18, 2026

Apr 17, 2026

LifeSci Capital Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $5 - Moomoo

Apr 17, 2026

Apr 16, 2026

Leerink reiterates Ovid Therapeutics stock rating on KCC2 potential By Investing.com - Investing.com South Africa

Apr 15, 2026

Leerink reiterates Ovid Therapeutics stock rating on KCC2 potential - Investing.com

Apr 15, 2026

Ovid Therapeutics' (OVID) "Outperform" Rating Reiterated at Wedbush - MarketBeat

Apr 15, 2026